← Back to Home

Wearable Injector Enters Blood Cancer Treatment as Sarclisa U.S. Approval Reshapes the Dosing Setting

The FDA has cleared a subcutaneous version of Sanofi’s multiple myeloma drug Sarclisa. The focus is not a new target, but compressing hours-long infusion into a treatment workflow closer to the rhythm of routine outpatient care.

By SURL BioNews

Progress in cancer drugs does not always come from an entirely new molecule. Sometimes, change happens after a patient sits down in the treatment chair: how long they wait, whether intravenous infusion is needed, how nursing staff are allocated. These seemingly logistical details gradually shape whether treatment can be sustained over the long term.

The U.S. Food and Drug Administration has approved Sanofi’s blood cancer drug Sarclisa Escena, the subcutaneous version of isatuximab-irfc, for the indications already covered by the existing intravenous formulation for multiple myeloma. Sanofi said this is the first cancer treatment in the United States that can be administered through an on-body injector, and that it can also be given manually as a subcutaneous injection by healthcare professionals.

Sarclisa itself is not a new drug. It is a monoclonal antibody targeting CD38 and is used to treat multiple myeloma; the FDA’s Drugs@FDA database also lists official application records including Sarclisa, BLA #761113, and Sanofi Aventis US. The core of this approval is moving the same treatment concept from intravenous infusion to subcutaneous administration, extending drug competition from efficacy to time, setting, and care workflow.

Sanofi said the approval is based in part on the Phase 3 IRAKLIA non-inferiority trial. The study is registered on ClinicalTrials.gov under NCT05405166 and compared Sarclisa delivered subcutaneously via an on-body injector with intravenous Sarclisa, both in combination with pomalidomide and dexamethasone. Data released by the company showed an objective response rate of 71.1% in the subcutaneous injection group and 70.5% in the intravenous injection group; systemic administration reactions were lower in the subcutaneous injection group. However, the publicly available summary currently provides the trial design and the main results disclosed by the company, while full safety details still need to be interpreted through the label and formal data.

For patients, the significance of this kind of formulation change lies in reducing treatment friction. Multiple myeloma often requires repeated treatment and long-term follow-up. If a single administration can reduce infusion time and the need for intravenous access, outpatient scheduling, caregiver time, and pressure on treatment chairs at medical institutions may all be affected. This does not mean treatment becomes simple, because antibody drugs still carry risks such as infection and infusion- or injection-related reactions, requiring monitoring according to prescribing information and by the healthcare team.

**Background Context**

This U.S. approval follows Europe. The European Commission approved the subcutaneous version of Sarclisa in June for use in combination with standard treatment under the existing indications for intravenous Sarclisa; in Europe, Sanofi has likewise made the CirCLIQ on-body injector central to its narrative. Successive approvals in Europe and the United States within a short period show that follow-on competition for cancer drugs is expanding from “whether they are effective” to “whether they can be delivered more efficiently.”

This shift also reminds people that innovation exists not only in target discovery inside laboratories, but also in workflow redesign at the point of care. For Sanofi, Sarclisa Escena is expected to strengthen its position in the multiple myeloma market; for patients and healthcare systems, the real test is whether the new mode of administration can consistently reduce burden in everyday use without sacrificing safety monitoring and treatment quality.

References

  1. SRN News
  2. Sanofi
  3. ClinicalTrials.gov
  4. U.S. Food and Drug Administration
  5. Sanofi